机构:[1]The First Clinical School of Medicine, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.[2]The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.[3]Guangdong Provincial Key Laboratory of Traditional Chinese Medicine and Acupuncture, Guangzhou, China.[4]Acupuncture and Rehabilitation Clinical School of Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.深圳市中医院深圳医学信息中心
This study was supported by Guangdong Provincial Key
Laboratory of Traditional Chinese Medicine and Acupuncture
(06), Zhangjiawei National Famous and Old TCM Experts
Inheritance Studio (National Administration of Traditional
Chinese Medicine [2012] No. 149), the special fund Innovating
and Strengthening the Hospital for preventive treatment
of disease of the First Affiliated Hospital of Guangzhou
University of Chinese Medicine (2019ZWB07), and Guangdong
Province Rural Science and Technology Commissioner
Project (KTPYJ2021026).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类|3 区医学
小类|3 区临床神经病学3 区神经科学
最新[2025]版:
大类|3 区医学
小类|3 区临床神经病学3 区神经科学
第一作者:
第一作者机构:[1]The First Clinical School of Medicine, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
共同第一作者:
通讯作者:
通讯机构:[2]The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.[3]Guangdong Provincial Key Laboratory of Traditional Chinese Medicine and Acupuncture, Guangzhou, China.
推荐引用方式(GB/T 7714):
Li Jialing,Xu Danghan,Liu Yingyu,et al.Acupuncture Treatment of Guillain-Barré Syndrome After Using Immune Checkpoint Inhibitors: A Case Report.[J].Frontiers in neurology.2022,13:908282.doi:10.3389/fneur.2022.908282.
APA:
Li Jialing,Xu Danghan,Liu Yingyu,Cao Yang,He Jun&Liao Muxi.(2022).Acupuncture Treatment of Guillain-Barré Syndrome After Using Immune Checkpoint Inhibitors: A Case Report..Frontiers in neurology,13,
MLA:
Li Jialing,et al."Acupuncture Treatment of Guillain-Barré Syndrome After Using Immune Checkpoint Inhibitors: A Case Report.".Frontiers in neurology 13.(2022):908282